Latest Conference Articles

Data from AAD 2025 examine the effect of GLP-1 RAs on HS among patients with overweight or obesity.

Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.

Stein Gold highlights her team's findings on tapinarof cream (Vtama) 1% from the 48-week ADORING 3 extension for those aged 2 to 17 with atopic dermatitis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

Susan Taylor, MD, discusses a study examining the effect of GLP-1 RA use relative to nonuse in central centrifugal cicatricial alopecia at AAD 2025.

This AAD 2025 interview features a discussion with Sonja Ständer, MD, new phase 3 findings from OLYMPIA 1 and 2 on nemolizumab in patients with prurigo nodularis.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

Combined analysis of data from a pair of post-registrational studies demonstrate the clinical profile and patient opinion on treatment with tirbanulin.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

In this interview at AAD 2025, Silverberg discusses important facts for dermatologists to know in the management of molluscum contagiosum.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

In this interview, Aguh answers several key questions about the efforts of the Skin of Color Society and improving diversity in clinical research.

HCPLive spoke with Golden at AAAAI on the pitfalls of diagnosing all patients with insect stings for insect sting allergies.

A panel discussion at the Skin of Color Society Scientific Symposium features 3 notable speakers highlighting dermatology residency questions and more.

Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

Findings were presented from the AROMA registry study in 3 abstracts at the AAAAI,WAO Joint Congress.

Casale discussed data from the phase 1b/2a BEACON study he presented at the AAAAI/WAO Joint Congress.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

This quiz, the second in a series of 4, tests your knowledge on cryosurgery and PDT recommendations for actinic keratosis based on the 2021 AAD guidelines.

HCPLive spoke with Lam at AAAAI about how allergists should establish endoscopic sinus surgery expectations with patients regarding risks and benefits ahead of the operation.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

Pongdee discussed research presented at the AAAAI/WAO Joint Congress that focused on improving diagnosis of indolent systemic mastocytosis.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.